In this context, it should be noted that in addition to the ~10% DLBCL cases showing nuclear NF-κB activity solely for the alternative pathway (indicated by nuclear staining of p52 but not p50) and ~20% of DLBCLs showing nuclear staining for both p50 and p52 [88], this indicates activation of both canonical and alternative NF-κB pathways [91]. The gene discussed is CD40; the disease is diffuse large B-cell lymphoma.